Solve Therapeutics has acquired Cereius, a company focused on developing targeted radiodiagnostics and radiotherapeutics for cancer patients. The acquisition complements SolveTx’s drug development expertise and expands its toolbox for oncology therapeutics. The deal includes upfront and milestone payments, as well as royalties on future product sales. SolveTx will continue developing the chemistry platform and building a research and development team.
Solve Therapeutics, Inc. (SolveTx), a biopharmaceutical company developing novel antibody-based therapeutics, announces the acquisition of Cereius, Inc. (Cereius), a private company developing innovative next-generation, targeted radiodiagnostics and radiotherapeutics for cancer patients. Cereius was co-founded by Professor Michael Zalutsky and Dr. Kimberly Lynn Blackwell around technology initially developed at Duke University and further advanced by the Cereius research team.
“Through the pioneering work of Duke University researchers and our early investment in the company, Cereius has built a conjugation chemistry platform that can be deployed with site-specific labeling,” said Eric Linsley, a General Partner at Mission BioCapital and board member of Cereius. “But this is just one possible application of the developed modular chemistry platform; swapping out the various components of the assembly allows for targeting of multiple types of cancers and delivering radionuclide diagnostics or therapeutics. This acquisition complements Duke University and Cereius innovations with extensive SolveTx drug development expertise.”
“We are excited to include the Cereius platform in our growing toolbox for developing cutting-edge oncology therapeutics,” said Dave Johnson, CEO of SolveTx. “Cereius technology has strong potential for expanding the utility of existing targeting antibodies and nanobodies. These next-generation radiolabeling chemistries and technology offer the potential to develop whole-body, contemporaneous imaging for patient selection in conjunction with the development of SolveTx targeted treatments and to provide value enhancement for partnering oncology companies seeking life-cycle product management opportunities.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Under the terms of the agreement, Cereius shareholders will receive an undisclosed upfront payment and are eligible to receive additional development, regulatory, and commercial milestone payments. In addition, Cereius shareholders are eligible to receive tiered royalties on net sales from therapeutic and diagnostic products that SolveTx successfully commercializes.
SolveTx will continue to refine the chemistry platform while developing targeted radionuclide therapeutics and evaluating companion radiodiagnostics for use together with other types of targeted cancer therapeutics. The company is building out a research and development team led by Jeffrey Schaal, PhD, Senior Vice President, Theragnostics, who is transitioning from Cereius to SolveTx. The company is investing in research facilities located at the recently completed Biolabs NC Gradlab building in downtown Durham, NC to support this development initiative.
Source: BioSpace